Moderator: Neal Rosen, MD, PhD, Director, Center for Mechanism-Based Therapeutics, Memorial Sloan-Kettering Cancer Center Panelists: Jeffrey A. Engelman, MD, PhD, Director of Thoracic Oncology and Director of Molecular Therapeutics, Massachusetts General Hospital Cancer Center Greg Plowman, MD, PhD, VP, Oncology Research Eli Lilly and Company David Solit, MD, Director, Developmental Therapeutics, Memorial Sloan-Kettering Cancer Center
Cancer Gene & Cell Therapy: Expanding Therapeutic Options With Living Drugs
Moderator: Mike Rice, MS, MBA, Senior Consultant, Defined Health Panelists: Estuardo Aguilar-Cordova, PhD, Chief Executive Officer Advantagene, Inc. Harry Gruber, MD, Chairman, Tocagen, Inc. Angela Shen, MD, MBA, Global Clinical Program Head, CTL019, Oncology Clinical Development, Novartis Pharmaceuticals Corp
Antibody-Drug Conjugates: Supercharging the Blockbuster Antibody Class
Moderator: Jeff Bockman, PhD, VP, Defined Health Panelists: Robert Cohen, MD, Calico Life Sciences Jonathan Drachman, MD, SVP, Research and Translational Medicine, Seattle Genetics Hans-Peter Gerber, PhD, VP, BioConjugate Discovery & Development, Oncology Research, Pfizer John Lambert, PhD, EVP, Research & Development & Chief Scientific Officer, ImmunoGen, Inc. Peter Kiener, Ph D, Chief Scientific Officer, […]